Publications by authors named "Marc Nasoff"

Claim this Profile
P
Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer.
Rahul R Aggarwal, Jacqueline Vuky, David VanderWeele, Matthew Rettig, Elisabeth I Heath, Marc Nasoff

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.
Léon Kautz, Grace Jung, Xin Du, Victoria Gabayan, Justin Chapman, Marc Nasoff

Blood· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma.
Sarah M Rue, Brendan P Eckelman, Jem A Efe, Kristin Bloink, Quinn L Deveraux, Marc Nasoff

Vet Immunol Immunopathol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes.
Yaiza Diaz-de-Durana, Janet Lau, Deborah Knee, Christophe Filippi, Marco Londei, Marc Nasoff

PLoS One· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids.
Jan Grünewald, Grady S Hunt, Liqun Dong, Frank Niessen, Ben G Wen, Marc Nasoff

Proc Natl Acad Sci U S A· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunochemical termination of self-tolerance.
Jan Grünewald, Meng-Lin Tsao, Roshan Perera, Liqun Dong, Frank Niessen, Marc Nasoff

Proc Natl Acad Sci U S A· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function.
Sabine Rottmann, Yan Wang, Marc Nasoff, Quinn L Deveraux, Kim C Quon

Proc Natl Acad Sci U S A· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle.
Yan-Guo Ren, Klaus W Wagner, Deborah A Knee, Pedro Aza-Blanc, Marc Nasoff

Mol Biol Cell· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway.
Yan Wang, Ingo H Engels, Deborah A Knee, Marc Nasoff, Quinn L Deveraux

Cancer Cell· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation and suppression of the TRAIL death-receptor pathway in chemotherapy sensitive and resistant follicular lymphoma cells.
Klaus W Wagner, Fred King, Ken Nomoto, Deborah A Knee, Garret Hampton, Marc Nasoff

Cancer Biol Ther· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis